Everand Logo

Welcome to Everand!

  • STAT

    Will the Speaker’s office finally spill the beans on its drug pricing plan?

    An insider's guide to the politics and policy of health care.
    by Nicholas Florko May 07, 2019 4 minutes

    D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

    STAT Scooplet: Wendell Primus set to break his silence

    House Speaker Nancy Pelosi’s health policy expert Wendell Primus is set to address a congressional drug pricing briefing Friday afternoon — his first public remarks since news broke that he has quietly been crafting the speaker’s own drug pricing plan. Primus has been in talks with the White House about his idea for using arbitration to negotiate the price of prescription drugs. And his efforts have single-handedly set off something of a drug-pricing-focused

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related Books & Audiobooks